Dyax and ICOS Enter Into License Agreement for Discovery of Therapeutic Antibodies
News May 23, 2006
Under the terms of the agreement, Dyax receives technology license fees from ICOS, as well as clinical milestone payments and royalties on net sales of any products that may result from ICOS's use of the Dyax libraries.
The agreement provides ICOS with a license to Dyax's antibody phage display technology and patent rights, as well as sublicenses to relevant third-party antibody phage display patents that may be used with Dyax's technology.
Henry E. Blair, Chairman and Chief Executive Officer of Dyax commented, "I'm pleased with the industry recognition of the value of our antibody technology and the sustained growth in Dyax's revenue-generating collaborations, as evidenced by this addition of ICOS to our long list of licensees."
"This arrangement will allow ICOS to utilize Dyax's state-of-the-art libraries of fully human monoclonal antibodies. We look forward to working with the talented team at ICOS, and to potential products moving forward under this license."
The spatial and temporal dynamics of proteins or organelles plays a crucial role in controlling various cellular processes and in development of diseases. However, acute control of activity at distinct locations within a cell cannot be achieved. A new chemo-optogenetic method enables tunable, reversible, and rapid control of activity at multiple subcellular compartments within a living cell.
Scientists from the UNC School of Medicine discovered that the anti-inflammatory protein NLRP12 normally helps protect mice against obesity and insulin resistance when they are fed a high-fat diet. The researchers also reported that the NLRP12 gene is underactive in people who are obese, making it a potential therapeutic target for treating obesity and diabetes.READ MORE